SCHEMBL5160553

SCHEMBL5160553

NC(=O)CC(=O)c1ccncn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.68
CTNNB1 P35222 2/20 0.48
WNT3A P56704 2/20 0.48
FAAH O00519 1/20 0.46
GRM4 Q14833 3/20 0.44
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MPO P05164 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP2A6 P11509 1/20 0.41
HSP90AA1 P07900 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
SIRT3 Q9NTG7 1/20 0.38
MKNK1 Q9BUB5 1/20 0.36
TBXA2R P21731 4/20 0.36
PLOD2 O00469 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293958 0.83 P2RX7 (0.59) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL12208551 0.81 P2RX7 (0.58) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL31627592 0.81 P2RX7 (1.00) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL107554 0.81 P2RX7 (1.00) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL4421799 0.79 P2RX7 (0.54) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL5161474 0.79 P2RX7 (0.54) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL29564726 0.78
SCHEMBL220487 0.78
SCHEMBL11844684 0.77 P2RX7 (0.53) P2RX7CTNNB1WNT3AFAAHGRM4
SCHEMBL5160321 0.77 P2RX7 (0.53) P2RX7CTNNB1WNT3AFAAHGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO P2RX7 2943/4885CTNNB1 3075/4885WNT3A 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.